COMPANY

Cyclarity Therapeutics

Keywords: atherosclerosis myocardial infarction Atherosclerotic Cardiovascular Disease Acute Coronary Syndromes UDP-003

Location: Novato, CA · source · Dec 30, 2024

Profile checked Oct 10, 2026

Timeline

Feb 25, 2025 Trial start Early phase 1: Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort source ↗

Dec 30, 2026 (ESTIMATED) · Early phase 1 · Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort · NCT06813339

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06813339	Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort	Early phase 1	Recruiting	Feb 25, 2025	Dec 30, 2026 (estimated)